Value20202021202220232024TTMSelling/general/admin expenses44.2 M37.87 M17.49 M16.81 M19.09 M—Research & development86.95 M129.03 M97.5 M87.65 M90.54 M—Operating income85.44 M130.68 M89.67 M97.3 M59.55 M—Non-Operating Income, Total——————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses——————Unusual income/expense——————Pretax income97.48 M125.11 M98.6 M116.46 M36.76 M—Equity in earnings——————Taxes0087 K371 K0—Non-controlling/minority interest16.41 M10.91 M7.89 M7.38 M0—After tax other income/expense——————Net income before discontinued operations0098.69 M100.05 M36.76 M—Discontinued operations97.48 M125.11 M15.35 M8.39 M0—Net income97.48 M125.11 M114.03 M108.44 M36.76 M—Dilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders——————Basic earnings per share (Basic EPS)——————Diluted earnings per share (Diluted EPS)——————Average basic shares outstanding——————Diluted shares outstanding——————EBITDA-120.4 M-164.24 M-86.82 M———EBIT-130.22 M-171.81 M-97.99 M-106.48 M-67.27 M—Cost of revenue36.27 M31.36 M1.77 M737 K0—Other cost of goods sold——————Depreciation & amortization (cash flow)9.82 M7.58 M11.17 M———
Cellectis S.A. - American Depositary Shares
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.